Overview

Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The study aims to describe the biochemical coagulation profile and investigate the effect of Low molecular weight heparin and Apixaban on this profile in patients with nephrotic syndrome.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Aarhus
Treatments:
Apixaban
Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin